TriSalus Life Sciences (TLSI) Q2 2026 earnings review
Sequential Rebound, but Stagnant YoY Growth Amid OpEx Bloat
TriSalus recovered from its Q1 sales force disruption, posting a 28% sequential revenue rebound to $11.4 million. However, the year-over-year picture is far less rosy: growth has decelerated to a stagnant 1.7%, a stark contrast to the 50%+ growth rates seen in 2025. While management praised the quarter's 'year-over-year and strong sequential growth', the reality is that Sales & Marketing expenses surged 59% to $11.4 million—meaning it cost the company exactly one dollar in S&M to generate one dollar in revenue. Gross margins remain an elite 86.8%, but massive execution risk looms over the second half of the year as the company maintained its $54-$57 million FY26 guidance, implying a monstrous acceleration is required in Q3 and Q4.
🐂 Bull Case
Gross margins expanded to 86.8% from 83.9% a year ago, driven by lower per-unit costs for the TriNav system. The core economics of the device remain highly attractive.
CMS established a new G-code extending reimbursement for vascular embolization into physician office-based labs (OBLs), opening a lucrative new site-of-service channel.
🐻 Bear Case
To hit the midpoint of FY26 guidance ($55.5M), TriSalus needs $35.2M in H2 revenue. This requires averaging $17.6M per quarter—a massive leap from the current $11.4M run rate.
The company doubled its commercial team, causing operating losses to widen to $9.8M. Adjusted EBITDA losses worsened 34% YoY. The payoff for this spend is not yet visible in YoY top-line growth.
⚖️ Verdict: 🔴
Bearish-leaning. The sequential recovery proves Q1's disruption is easing, but 1.7% YoY growth is deeply concerning for a commercial-stage medtech company valued on its growth trajectory. The 'hockey stick' guidance for H2 requires flawless execution.
Key Themes
The H2 Guidance Mountain
Management maintained full-year revenue guidance of $54M to $57M. With H1 actuals sitting at $20.3M, the implied H2 requirement is $33.7M to $36.7M. This implies accelerating H2 YoY growth to approximately 42% (compared to H1's flat YoY performance). Relying heavily on the newly expanded sales reps reaching full productivity is a high-wire act, particularly with the delayed TriNav Advance FDA clearance removing a potential H2 catalyst.
Sales & Marketing Spend Eating the Top Line
Reversing profitability trends are evident as S&M expenses surged to $11.4M—matching total revenue for the quarter. In 25Q2, S&M was 64% of revenue; today, it is 100%. While this reflects the deliberate strategy to double the commercial organization, the lack of commensurate YoY revenue growth (1.7%) suggests the new reps are either ramping slower than expected or facing stiffer market resistance.
Elite Gross Margin Expansion
Gross margins are accelerating, posting an 86.8% print compared to 83.9% in the prior year period. Management directly attributes this to a reduction in cost per TriNav unit. This structural profitability at the unit level provides a strong foundation if commercial leverage ever materializes.
New CMS Reimbursement Code (G-code)
A crucial structural driver was announced: CMS established a G-code extending reimbursement for vascular embolization procedures using a pressure-generating catheter into the physician office-based lab (OBL) site of service. This expands the Total Addressable Market by decentralizing where TriNav can be profitably utilized, though the final reimbursement rate is still pending.
Building the Clinical Moat
TriSalus continues to heavily arm its expanded sales force with data. The company recently submitted data from the PEDIR study (evaluating tumor-to-normal ratio in HCC) for publication and hosted a KOL event focused on real-world evidence for PEDD in liver cancer. Proving that the Pressure-Enabled Drug Delivery (PEDD) technology structurally outperforms standard microcatheters remains the core adoption driver.
Reliance on Liver Base Ahead of New Indication Maturation
While TriSalus is targeting massive TAM expansions in GAE (knee) and UAE (uterine fibroids), 100% of current commercial reliance remains on liver embolization. If liver growth has organically plateaued at a ~$45M run-rate, the company's valuation hinges entirely on successful pivots to these adjacent markets, which are still in early clinical and registry phases.
Other KPIs
Reversing. The adjusted loss worsened from -$5.3M a year ago. This reflects the intense structural cost of building out the commercial organization. The company previously delayed its target to achieve cash flow breakeven to 2026; achieving this looks increasingly difficult given current S&M run-rates.
Stable. Bolstered by the $46.0M Q1 equity offering, the company maintains healthy liquidity. Management reiterates this provides 'sufficient cash runway to fully fund commercial expansion and pipeline development.' Operating cash burn will dictate how long this runway truly lasts.
Stable YoY (vs -$9.0M in 25Q2). It's important to note this includes a $1.6M non-cash net gain related to fair value derivatives. Excluding this financial engineering, the underlying operational loss is deeper than the headline net loss suggests.
Guidance
Accelerating implied growth. Maintaining this guidance range (which represents 19% to 26% YoY growth) requires the company to deliver between $33.7M and $36.7M in the second half of the year. Given H1 actuals were $20.3M (virtually flat YoY), this implies an extreme acceleration in H2. Investors should heavily discount the probability of hitting the high end of this range.
Key Questions
Bridging the H2 Guidance Gap
With H1 revenue flat YoY at $20.3M, what specific metrics (e.g., rep productivity, new account openings) give you confidence that H2 revenue will accelerate to the ~$35M needed to hit the midpoint of guidance?
Sales Rep Productivity Timeline
Sales and marketing expense reached 100% of revenue this quarter. Are the new sales reps hired in late 2025/early 2026 tracking to your internal 6-to-9 month productivity ramp expectations?
CMS G-Code Economics
Regarding the new OBL site-of-service G-code, what are your expectations for the final reimbursement rate, and how quickly can your sales team convert this regulatory win into new orders?
TriNav Advance Timeline
Since TriNav Advance was removed from 2026 guidance due to FDA delays, have you received any updated feedback or specific requests from the agency that inform a new timeline for clearance?